Janina R Behrens1,2, Ludwig Rasche1,3, Rene M Gieß1,3, Catherina Pfuhl1,3, Katharina Wakonig1,3, Erik Freitag1,3, Katrin Deuschle2,4, Judith Bellmann-Strobl1,2,5, Friedemann Paul1,2,3,5, Klemens Ruprecht2,3, Jan Dörr1,2,5. 1. NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany. 2. Clinical and Experimental Multiple Sclerosis Research Center, Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. 3. Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. 4. Department of Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany. 5. Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Abstract
BACKGROUND AND PURPOSE: Low 25-hydroxyvitamin D [25(OH)D] levels correlate with higher disease activity in patients with multiple sclerosis (MS). However, it is not clear whether low 25(OH)D levels directly contribute to increased disease activity or merely represent a consequence of reduced endogenous vitamin D synthesis in more disabled MS patients. Furthermore, recent data suggest that bioavailable vitamin D, which also integrates the levels of vitamin D binding proteins and albumin, could be a biologically more relevant parameter than 25(OH)D. METHODS: Measured de-seasonalized 25(OH)D3 and vitamin D binding protein and calculated bioavailable and free vitamin D were compared in the baseline serum samples of 76 patients with clinically isolated syndrome enrolled in a longitudinal observational study and in 76 age- and sex-matched healthy controls (HC). RESULTS: 25(OH)D3 levels were lower in patients with clinically isolated syndrome (P = 0.002) than in HC, and more patients (8/76, 10.5%) than HC (1/76, 1.3%) had 25(OH)D3 levels <25 nmol/l (P = 0.03). In contrast, levels of 25(OH)D2, vitamin D binding protein and calculated levels of free and bioavailable vitamin D did not differ between the two groups. CONCLUSIONS: Lower 25(OH)D3 levels already in the earliest phase of disease and in clinically hardly affected patients suggest that low 25(OH)D3 levels are rather a risk factor for than a consequence of MS. Nevertheless, because bioavailable vitamin D levels did not differ between the two groups, the mechanism underlying the association of 25(OH)D3 and MS does not appear to be related to reduced bioavailability of vitamin D.
BACKGROUND AND PURPOSE: Low 25-hydroxyvitamin D [25(OH)D] levels correlate with higher disease activity in patients with multiple sclerosis (MS). However, it is not clear whether low 25(OH)D levels directly contribute to increased disease activity or merely represent a consequence of reduced endogenous vitamin D synthesis in more disabled MS patients. Furthermore, recent data suggest that bioavailable vitamin D, which also integrates the levels of vitamin D binding proteins and albumin, could be a biologically more relevant parameter than 25(OH)D. METHODS: Measured de-seasonalized 25(OH)D3 and vitamin D binding protein and calculated bioavailable and free vitamin D were compared in the baseline serum samples of 76 patients with clinically isolated syndrome enrolled in a longitudinal observational study and in 76 age- and sex-matched healthy controls (HC). RESULTS: 25(OH)D3 levels were lower in patients with clinically isolated syndrome (P = 0.002) than in HC, and more patients (8/76, 10.5%) than HC (1/76, 1.3%) had 25(OH)D3 levels <25 nmol/l (P = 0.03). In contrast, levels of 25(OH)D2, vitamin D binding protein and calculated levels of free and bioavailable vitamin D did not differ between the two groups. CONCLUSIONS: Lower 25(OH)D3 levels already in the earliest phase of disease and in clinically hardly affected patients suggest that low 25(OH)D3 levels are rather a risk factor for than a consequence of MS. Nevertheless, because bioavailable vitamin D levels did not differ between the two groups, the mechanism underlying the association of 25(OH)D3 and MS does not appear to be related to reduced bioavailability of vitamin D.
Authors: Marina Eloi; Daniela Vargas Horvath; João Carlos Ortega; Mônica Simon Prado; Luis Eduardo Coelho Andrade; Vera Lúcia Szejnfeld; Charlles Heldan de Moura Castro Journal: PLoS One Date: 2017-01-13 Impact factor: 3.240
Authors: Anja Mähler; Andras Balogh; Ilona Csizmadia; Lars Klug; Markus Kleinewietfeld; Jochen Steiniger; Urša Šušnjar; Dominik N Müller; Michael Boschmann; Friedemann Paul Journal: Front Immunol Date: 2018-11-29 Impact factor: 7.561
Authors: Katherine A Sauder; Alexandra V Stamatoiu; Elina Leshchinskaya; Brandy M Ringham; Deborah H Glueck; Dana Dabelea Journal: J Am Heart Assoc Date: 2019-05-07 Impact factor: 5.501
Authors: Priscilla Bäcker-Koduah; Carmen Infante-Duarte; Federico Ivaldi; Antonio Uccelli; Judith Bellmann-Strobl; Klaus-Dieter Wernecke; Michael Sy; Michael Demetriou; Jan Dörr; Friedemann Paul; Alexander Ulrich Brandt Journal: Ann Clin Transl Neurol Date: 2020-08-23 Impact factor: 4.511